Test Discontinuation Memorandum

Effective August 3, 2015, Baylor Miraca Genetics Laboratories (BMGL) will begin performing BRCA1 & BRCA2 sequencing analysis as an in-house test. As a result, BMGL will discontinue use of the following test code:

  • Test code 1220 – BRCA1/2 Sequence & Deletion/Duplication Analysis

For all new orders, please use the following test code, which will replace test code 1220:

  • Test code 22350 – BRCA1 & BRCA2 Comprehensive Panel – NGS
Previous Post
Test Discontinuation Memorandum
Next Post
Test Update Memorandum